CDP 323

Drug Profile

CDP 323

Alternative Names: CDP323

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator UCB
  • Class Anti-inflammatories; Small molecules
  • Mechanism of Action Integrin alpha4beta1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Crohn's disease; Inflammatory bowel diseases; Multiple sclerosis; Rheumatoid arthritis

Most Recent Events

  • 30 Jun 2009 Discontinued - Phase-I for Multiple sclerosis in United Kingdom (PO)
  • 30 Jun 2009 Discontinued - Phase-II for Multiple sclerosis in Belgium (PO)
  • 30 Jun 2009 Discontinued - Phase-II for Multiple sclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top